64Cu-DOTATATE PET/CT 用于已知或疑似生长抑素受体阳性神经内分泌肿瘤患者的显像:美国首项前瞻性、读者设盲临床试验结果
本项美国前瞻性、读者设盲III期研究先在12例患者中确定64Cu-DOTATATE最低诊断质量剂量,再用该剂量对21名健康志愿者和42例NET阳性患者行PET/CT,由3名设盲核医学医师独立判读。结果显示148 MBq(4.0 mCi)为最佳剂量,多数读片诊断灵敏度90.9%、特异度96.6%,校正标准真相误判后灵敏度100.0%、特异度96.8%,无药物相关不良事件。
要点
- 剂量爬坡研究确定64Cu-DOTATATE最佳显像剂量为148 MBq(4.0 mCi)。
- 多数读片诊断NET的灵敏度90.9%、特异度96.6%,校正后灵敏度100.0%、特异度96.8%。
- 未观察到与64Cu-DOTATATE相关的不良事件或严重不良事件。
核心结论
- 64Cu-DOTATATE PET/CT是一种安全的显像技术,在148 MBq(4.0 mCi)剂量下可高质量、准确地检测表达生长抑素受体的NET。
研究设计与样本
- III期前瞻性、读者设盲临床试验,先行剂量爬坡研究(12例患者分3组:111 MBq、148 MBq、185 MBq±10%),再以确定剂量对21名健康志愿者和42例NET阳性患者行PET/CT,由3名设盲核医学医师独立判读并与标准真相比较。
主要发现
- 剂量爬坡研究确定148 MBq(4.0 mCi)为获得诊断质量PET/CT图像的最佳剂量。
- 3名独立读者初始多数读片诊断NET的灵敏度为90.9%(P=0.0042)、特异度为96.6%(P<0.0001)。
- 校正初始标准真相误判后,灵敏度为100.0%、特异度为96.8%。
- 读者间和读者内可靠性优秀,区分局限性与转移性疾病的能力亦良好。
- 未观察到与64Cu-DOTATATE相关的不良事件,未观察到严重不良事件。
关键数值与推荐
- 诊断性能指标包括灵敏度、特异度、阴性预测值、阳性预测值及准确率,以患者特异性标准真相为参照。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Studies demonstrate that the investigational 64Cu-DOTATATE radiopharmaceutical may provide diagnostic and logistical benefits over available imaging agents for patients with somatostatin receptor (SSTR)-positive neuroendocrine tumors (NETs). Accordingly, we aimed to prospectively determine the lowest dose of 64Cu-DOTATATE that facilitates diagnostic-quality scans and evaluated the diagnostic performance and safety in a phase III study of patients with SSTR-expressing NETs. Methods: A dose-ranging study was conducted on 12 patients divided into 3 dose groups (111 MBq [3.0 mCi], 148 MBq [4.0 mCi], and 185 MBq [5.0 mCi] ± 10%) to determine the lowest dose of 64Cu-DOTATATE that produced diagnostic-quality PET/CT images. Using the 64Cu-DOTATATE dose identified in the dose-ranging study, 3 independent nuclear medicine physicians who were masked to all clinical information read PET/CT scans from 21 healthy volunteers and 42 NET-positive patients to determine those with disease or no disease, as well as those with localized versus metastatic status. Masked-reader evaluations were compared with a patient-specific standard of truth, which was established by an independent oncologist who used all previously available pathology, clinical, and conventional imaging data. Diagnostic performance calculated for 64Cu-DOTATATE included sensitivity, specificity, negative predictive value, positive predictive value, and accuracy. Inter- and intrareader reliability, as well as ability to differentiate between localized and metastatic disease, was also determined. Adverse events were recorded from 64Cu-DOTATATE injection through 48 h after injection. Results: The dose-ranging study identified 148 MBq (4.0 mCi) as the optimal dose to obtain diagnostic-quality PET/CT images. After database lock, diagnostic performance from an initial majority read of the 3 independent readers showed a significant 90.9% sensitivity (P = 0.0042) and 96.6% specificity (P < 0.0001) for detecting NETs, which translated to a 100.0% sensitivity and 96.8% specificity after correcting for an initial standard-of-truth misread. Excellent inter- and intrareader reliability, as well as ability to distinguish between localized and metastatic disease, was also noted. No adverse events were related to 64Cu-DOTATATE, and no serious adverse events were observed. Conclusion:64Cu-DOTATATE PET/CT is a safe imaging technique that provides high-quality and accurate images at a dose of 148 MBq (4.0 mCi) for the detection of somatostatin-expressing NETs.
引用
- Delpassand ES, Ranganathan D, Wagh N, et al. 64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial. J Nucl Med. 2020. PMID: 31924723. doi:10.2967/jnumed.119.236091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。